Hepatology Research

Papers
(The H4-Index of Hepatology Research is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Reply to Letter to the Editor: Regarding the “Hepatitis B surface antigen glycan isomer is a predictor of the development of hepatocellular carcinoma during nucleoside/nucleotide analog therapy”195
Efficacy and Safety of Direct Oral Anticoagulants in Budd–Chiari Syndrome After Percutaneous Recanalization64
Immune‐related adverse event detection in liver cancer patients treated with immune checkpoint inhibitors: Nationwide exploratory survey in Japan63
Deceased Donation Disparities in East Asia—A Tale of Two Systems49
Factors associated with low hepatitis B surface antigen levels in chronic hepatitis B patients treated with nucleot(s)ide analogs47
Conditional recurrence analysis of intrahepatic cholangiocarcinoma: Changes in recurrence rate and survival after recurrence resection by disease‐free interval44
Lenvatinib radiofrequency ablation sequential therapy offers survival benefits for patients with unresectable hepatocellular carcinoma at intermediate stage and the liver reserve of Child–Pugh A categ38
Significance of changes in tumor markers in patients treated with durvalumab plus tremelimumab combination therapy as a surrogate marker for tumor response to unresectable hepatocellular carcinoma38
Development and validation of a prognostic model for 90‐day survival in patients with alcohol‐associated cirrhosis and acute decompensation37
Reversion of liver cirrhosis after endovascular treatment in Chinese patients with Budd–Chiari syndrome35
Role of PAR1 −506 deletion/insertion polymorphism in primary sclerosing cholangitis35
Factors associated with portopulmonary hypertension34
Sofosbuvir/velpatasvir and glecaprevir/pibrentasvir: how should we choose among these two latest and probably the last regimens?33
Initial Experience With Nalmefene in Alcohol‐Related Liver Disease: A Real‐World Retrospective Study29
Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy27
The metabolic evaluation of pemafibrate in nonalcoholic fatty liver disease‐related cardiovascular diseases25
Combined effect of histological findings and diabetes mellitus on liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease24
Prognostic value of virtual portal pressure gradient response in compensated cirrhotic patients treated with carvedilol24
Prediction of intrahepatic covalently closed circular DNA levels in patients with resolved hepatitis B virus infection: Impact of serum antibody to hepatitis B core antigen titers23
Rechallenge of Atezolizumab Plus Bevacizumab Therapy in Patients With Unresectable Hepatocellular Carcinoma23
Acknowledgment22
The change from NAFLD to MAFLD expands fatty liver information flow22
Continuous Intravenous Infusion of Hepatocyte Growth Factor Promotes the Development of a Fibrolytic Phenotype in Hepatic Macrophages and Stellate Cells in a Rat Model of Bile Duct Ligation22
0.88436007499695